



PRESS RELEASE

Perspixon' groundwork publication regarding high-throughput technology for multi-specific antibodies

Frankfurt, July 2023

Joerg Birkenfeld, Chief Scientific Officer of Perspixon Biotech, has co-authored a research paper in the peer-review specialist Journal of Analytical Chemistry.

The research focuses on a novel workflow that enables the accurate assessment of correct assembly for multi-specific antibodies. This approach allows for the analysis of a wide range of up to 1.000 complex molecules, including next-generation intricate Tri-Specific Antibodies, and provides for remarkable results in less than three weeks. The advanced methodology evaluates critical molecule properties such as the precise pairing of heavy and light chains and identifies potential product-related impurities.

Please see here for a full download of the article: <https://pubs.acs.org/doi/abs/10.1021/acs.analchem.3c00742>.

"We are proud and grateful to be able to work with an exceptional scientist like Joerg. His work is revolutionary, and his experience in high-throughput biologics is extremely valuable, not only for Perspixon ", says Matthias Wiedenfels, CEO of Perspixon Biotech.

For further media information/interview opportunities please contact:

Dr. José Airas

T +49 (0)177 577 9828

E info@perspixonbio.tech

Notes to editors:

Perspixon is a biotech company specialized in multi-specific antibodies. Perspixon creates next-generation biotherapeutics through an end-to-end automated discovery platform. The company aims to radically accelerate the technical development of biological drug modalities with predictive AI, significantly reducing drug development times and costs. The roPROTix platform automatically generates tens of thousands of in-silico designed modalities and analyses them for key functional and biophysical properties in a parallelized approach. This digitally integrated process generates interrelated and multidimensional datasets of unprecedented quantity and quality, which feed directly into ML algorithms that drive the in-silico design engine.

Perspixon is headquartered in the FIZ Frankfurt Innovation Center for Biotechnology, Germany